Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $8.2 million.

  • PROCEPT BioRobotics' Other Accumulated Expenses rose 363.48% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 363.48%. This contributed to the annual value of $8.1 million for FY2024, which is 2803.1% up from last year.
  • As of Q3 2025, PROCEPT BioRobotics' Other Accumulated Expenses stood at $8.2 million, which was up 363.48% from $9.7 million recorded in Q2 2025.
  • PROCEPT BioRobotics' 5-year Other Accumulated Expenses high stood at $9.7 million for Q2 2025, and its period low was $2.8 million during Q3 2021.
  • Its 5-year average for Other Accumulated Expenses is $6.9 million, with a median of $7.8 million in 2024.
  • As far as peak fluctuations go, PROCEPT BioRobotics' Other Accumulated Expenses skyrocketed by 13308.04% in 2021, and later tumbled by 1539.9% in 2023.
  • Quarter analysis of 5 years shows PROCEPT BioRobotics' Other Accumulated Expenses stood at $4.6 million in 2021, then skyrocketed by 62.07% to $7.5 million in 2022, then fell by 15.4% to $6.3 million in 2023, then increased by 28.03% to $8.1 million in 2024, then increased by 1.16% to $8.2 million in 2025.
  • Its Other Accumulated Expenses stands at $8.2 million for Q3 2025, versus $9.7 million for Q2 2025 and $8.5 million for Q1 2025.